Apr 30

Mesoblast Stem Cell Therapy Study shows 83% Survival in patients on Ventilators from COVID-19

News was announced today from Biospace that patients with ARDS (Acute Respiratory Distress) demonstrated an 83% survival after 2 IV infusions of Mesoblast’s product Ryoncil (remestemcel-L). This med is NOT FDA approved for treating COVID-19  according to BioSpace. In the study, 9/12 patients came off ventilators within 10 days, with 7 patients discharged from the hospital. According the report patients were treated in New York City’s Mt Sinai hospital under an emergency investigational new drug (IND) application or via expanded access portal....

Jul 16

Comparing PRP and prolotherapy in the treatment of SI joint dysfunction

[section_tc][column_tc span='12'][text_tc trigger_pt='0' duration='1000' delay='0']Low back pain (LBP) is a significant source of morbidity that affects a significant portion of the population. While initially a mainstay in therapy, surgical interventions have come under intense scrutiny as research has questioned their efficacy in addressing LBP. Nonspecific LBP (NSLBP) is particularly difficult to treat because multiple etiologies can contribute to ongoing pain. Mechanical dysfunction of the sacroiliac joint (SIJ) has been targeted as a common source of low back pain amenable to...

Jun 2

A Conversation on Regenerative Medicine with Drs. Malanga and Mautner

[section_tc][column_tc span='12'][text_tc trigger_pt='0' duration='1000' delay='0']Regenerative medicine experts and TOBI faculty Dr. Gerry Malanga and Dr. Ken Mautner recently sat down with Dr. Jonothan Halperin to discuss the basics of regenerative medicine as well as the current state of literature possible future directions. We’ve provided a brief synopsis below, but encourage you to dive into this fascinating conversation from two of the thought-leaders in this area.Synopsis:The conversation starts by summarizing the past and current state of regenerative therapies. While these therapies...